171 related articles for article (PubMed ID: 22463698)
1. The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.
Park KW; Park BE; Kang SH; Park JJ; Lee SP; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS;
Trials; 2012 Mar; 13():29. PubMed ID: 22463698
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS
Trials; 2015 Sep; 16():409. PubMed ID: 26374625
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
Kim CH; Park KW; Kang J; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
Circ J; 2019 Jun; 83(7):1489-1497. PubMed ID: 31155604
[TBL] [Abstract][Full Text] [Related]
6. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
van Geuns RJ; Chun-Chin C; McEntegart MB; Merkulov E; Kretov E; Lesiak M; O'Kane P; Hanratty CG; Bressollette E; Silvestri M; Wlodarczak A; Barragan P; Anderson R; Protopopov A; Peace A; Menown I; Rocchiccioli P; Onuma Y; Oldroyd KG
EuroIntervention; 2022 Apr; 17(18):1467-1476. PubMed ID: 35285803
[TBL] [Abstract][Full Text] [Related]
7. PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.
Gao R; Han Y; Yang Y; Zhang J; Hou Y; Wang H; Li H; Fang Q; Yu B; Xu B; Allocco DJ; Dawkins KD
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():716-23. PubMed ID: 25631909
[TBL] [Abstract][Full Text] [Related]
8. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
9. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of acute stent malapposition between platinum-chromium versus cobalt-chromium everolimus-eluting stents.
Kim BK; Shin DH; Kim JS; Ko YG; Choi D; Jang Y; Hong MK
Int J Cardiovasc Imaging; 2015 Feb; 31(2):269-77. PubMed ID: 25345751
[TBL] [Abstract][Full Text] [Related]
11. Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).
Meredith IT; Teirstein PS; Bouchard A; Carrié D; Möllmann H; Oldroyd KG; Hall J; Allocco DJ; Dawkins KD; Stone GW
Am J Cardiol; 2014 Apr; 113(7):1117-23. PubMed ID: 24530167
[TBL] [Abstract][Full Text] [Related]
12. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
[TBL] [Abstract][Full Text] [Related]
13. Comparison of platinum chromium everolimus-eluting stent with cobalt chromium everolimus-eluting stent in unselected patients undergoing percutaneous coronary intervention.
Li RG; Lee CH; Low A; Chan M; Chan KH; Richards AM; Qu XK; Fang WY; Tan HC
Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2213-20. PubMed ID: 26166645
[TBL] [Abstract][Full Text] [Related]
14. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
15. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
[TBL] [Abstract][Full Text] [Related]
16. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease.
Lee PH; Kwon O; Ahn JM; Lee CH; Kang DY; Lee JB; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
J Am Coll Cardiol; 2018 Feb; 71(8):832-841. PubMed ID: 29471933
[TBL] [Abstract][Full Text] [Related]
18. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries.
Kwon O; Kang SH; Lee JB; Ahn JM; Lee CH; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Coron Artery Dis; 2019 Jun; 30(4):255-262. PubMed ID: 30883430
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]